West Pharmaceutical Services raises 2024 adjusted EPS expectations and net sales guidance due to favorable currency conditions.
West Pharmaceutical Services, Inc. (WST) has updated its 2024 guidance, raising adjusted EPS expectations to $6.55-$6.75 and net sales guidance to $2.875-$2.905 billion, influenced by favorable currency conditions. In Q3, the company reported a profit of $136 million ($1.85 per share), surpassing expectations of $1.50, despite a 0.1% revenue decline to $746.9 million. The Board approved a 5% increase in the fourth-quarter dividend to $0.21 per share.
October 24, 2024
10 Articles